CARGO Therapeutics, Inc. (CRGX)
NASDAQ: CRGX · Real-Time Price · USD
4.390
-0.070 (-1.57%)
Jul 7, 2025, 4:00 PM - Market closed
CARGO Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover CARGO Therapeutics stock have a consensus rating of "Hold" and an average price target of $4.67, which forecasts a 6.38% increase in the stock price over the next year. The lowest target is $3 and the highest is $7.
Price Target: $4.67 (+6.38%)
Analyst Consensus: Hold
* Price targets were last updated on Jan 30, 2025.
Analyst Ratings
The average analyst rating for CARGO Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $32 → $7 | Strong Buy → Hold | Downgrades | $32 → $7 | +59.45% | Jan 30, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $34 → $4 | Buy → Hold | Downgrades | $34 → $4 | -8.88% | Jan 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 30, 2025 |
| JP Morgan | JP Morgan | Buy → Sell Downgrades n/a | Buy → Sell | Downgrades | n/a | n/a | Jan 30, 2025 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 30, 2025 |
Financial Forecast
Revenue This Year
201.21M
from 127.50M
Increased by 57.81%
Revenue Next Year
n/a
from 201.21M
EPS This Year
-2.76
from -3.72
EPS Next Year
-2.88
from -2.76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.56 | -1.85 | -2.12 | ||
| Avg | -2.76 | -2.88 | -2.56 | ||
| Low | -4.31 | -4.70 | -2.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.